Stock Analysis of Alnylam Pharmaceuticals Inc (ALNY) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALNY
Close 151.22
Change 3.82 / 2.59 %
Volume 934860
Vol Change 398717 / 74.37 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Very Low Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Alnylam Pharmaceuticals Inc
PE (TTM)

-57.80

Very Poor
Price / Book

-75.39

Very Poor
Price / Sales

9.58

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

19128.12 M

Enterprise Value

19432.71 M

ROA (TTM)

-9.08

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-16.58

Very Poor
Revenue

66.14 %

1723.61 M
Net Profit

54.93 %

-509865.00 K
Debt to Equity

-5.06

Very Poor
Altman Z Score

1.05

Not Good
Quick Ratio

2.99

Good
Cash Ratio

2.52

Good


Highs/Lows of Alnylam Pharmaceuticals Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week151.37 0.099 % 1.59 % 152.67144.7313-May-2416-May-24
Two Week150.31 0.605 % 4.60 % 155.49144.7308-May-2416-May-24
One Month146.72 3.07 % 4.86 % 155.49141.97508-May-2425-Apr-24
Three Month147.0 2.87 % 5.82 % 164.02141.97522-Feb-2425-Apr-24
Six Months168.97 10.50 % 17.50 % 199.38141.97509-Jan-2425-Apr-24
One year190.97 20.81 % 28.89 % 218.88141.97517-Jul-2325-Apr-24
Two year124.87 21.10 % 32.16 % 242.97141.97521-Dec-2225-Apr-24
Five year68.73 120.02 % 84.16 % 242.9765.8121-Dec-2220-May-19
Ten year57.3 163.91 % 182.08 % 242.9731.3821-Dec-2203-Nov-16


Technical View of Alnylam Pharmaceuticals Inc
RSI

53.49

Neutral
MACD

0.112

Strong Bullish
ADX

12.68

Neutral
Super Trend

155.42

Mild Bearish
Williams %R

-35.61

Neutral
CCI

14.01

Neutral


EMA 5

149.75

Strong Bullish
EMA 15

149.54

Neutral
EMA 50

151.67

Whipsaw
EMA 100

157.93

Mild Bearish
SMA 100

162.19

Mild Bearish
SMA 200

169.25

Mild Bearish
SMA 5 / 20

149.37 / 148.35

Bullish
SMA 15 / 50

149.55 / 149.27

Mild Bullish
SMA 50 / 200

149.27 / 169.25

Strong Bearish




Charts of Alnylam Pharmaceuticals Inc


Returns of Alnylam Pharmaceuticals Inc with Peers
Period / StockALNYBGNEGMABTEVA
1 Week-0.099%1.42%2.92%1.88%
1 Mth3.07%27.59%0.748%24.52%
3 Mth2.87%15.38%3.27%25.19%
6mth-10.50%-9.59%-7.23%86.07%
1 Year-20.81%-28.41%-28.64%100.49%
2 Year21.10%32.40%0.919%106.07%
5 Years120.02%23.72%72.15%42.73%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Alnylam Pharmaceuticals Inc with Peers
Ratio / StockALNYBGNEGMABTEVA
PE-57.80-148112.821.16-37.37
P/B-75.3930253.680.2102.33
ROA-9.08-13.3716.07-1.15
ROE0-20.4318.03-6.55
Debt To Equity-5.060.2570.00282.64
Revenue1723.61 M
66.14 % 		2204.47 M
55.69 % 		17023.00 M
16.64 % 		15846.00 M
6.17 %
Net Income-509865.00 K
54.93 % 		-959490.00 K
52.12 % 		4296.00 M
22.20 % 		-559000.00 K
76.24 %


Technicals of Alnylam Pharmaceuticals Inc with Peers
Technical / StockALNYBGNEGMABTEVA-
ADX12.6822.5413.1635.47
CMF-0.2030.0650.02140.213
MFI57.6564.4759.1065.52
RSI53.4965.3854.0068.94
MACD Abv SignalTrueTrueTrueTrue
Price Above 50 MATrueTrueTrueTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Alnylam Pharmaceuticals Inc

Address : 675 West Kendall Street, Cambridge, MA, United States, 02142
Tel : 617 551 8200
URL : https://www.alnylam.com
Code : ALNY, ISIN : US02043Q1076, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 28_May_2004
Employee Count : 2100

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)